Vir Biotechnology, a ‘Shock and Awe’ Startup, Bets on Infectious Disease with $500M+

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.